Share on StockTwits

United Therapeutics (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 9,066 shares of United Therapeutics stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $98.22, for a total value of $890,462.52. Following the completion of the sale, the chief executive officer now directly owns 140 shares of the company’s stock, valued at approximately $13,751. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of United Therapeutics (NASDAQ:UTHR) traded down 7.97% on Friday, hitting $89.63. 1,697,500 shares of the company’s stock traded hands. United Therapeutics has a 52 week low of $61.23 and a 52 week high of $116.65. The stock’s 50-day moving average is $99.36 and its 200-day moving average is $99.53. The company has a market cap of $4.318 billion and a P/E ratio of 21.16.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $1.77 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.65 by $0.12. The company had revenue of $289.40 million for the quarter, compared to the consensus estimate of $300.14 million. During the same quarter last year, the company posted $1.19 earnings per share. United Therapeutics’s revenue was up 18.1% compared to the same quarter last year. On average, analysts predict that United Therapeutics will post $7.77 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of United Therapeutics in a research note on Tuesday, May 27th. They now have a $104.00 price target on the stock. Finally, analysts at Standpoint Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 7th. They now have a $118.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. United Therapeutics presently has an average rating of “Hold” and an average target price of $95.93.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.